Evolution of XDR-TB. A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal

Similar documents
The emerging threat of multidrug resistant TB: Global and local challenges and solutions

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics

Transmission of XDR TB

HIV and Drug-Resistant TB Reflections from rural Tugela Ferry

Diagnosis of drug resistant TB

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

Treatment of Extensively Drug Resistant Tuberculosis Among Patients with HIV Infection in South Africa

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

9 Tuberculosis. Introduction. Lieve Vanleeuw and Marian Loveday

Management of Drug-resistant Tuberculosis (DR-TB)

Addressing TB in a High HIV Prevalence Setting in Rural South Africa: the 3Is

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

KWAZULU-NATAL. connecting. collecting. collaborating A SUPPORT SERVICES DIRECTORY SERIES

Progress Report March 2016

SA: Percentage [Source: DHIS]

5 PMTCT Indicators Linda Mureithi

2014/15 % 2013/14 % 2012/13 %

9 Reproductive health

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building

XDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps

Final Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR)

Expanded Programme on Immunisation South Africa Revised immunisation schedule from December 2015

Progress towards Malaria Elimination in South Africa. Durban, South Africa 10 September 2011

10 HIV Thesandree Padayachee

Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa

9 Tuberculosis Marian Loveday and Lieve Vanleeuw

Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa

Transmission of MDR/XDR Tuberculosis in Shanghai. Qian Gao Shanghai Medical College Fudan University

Kristina Wallengren, PhD MPH

The National Strategic Plan for HIV, TB and STIs: April 2017-March 2022

Update on Management of

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Online Annexes (5-8)

11 HIV and AIDS Male condom distribution coverage. Tshepo Molapo, Lebogang Schultz, Refilwe Sello and Lesego Mawela

Online Annexes (5-8)

RESEARCH. 507 June 2017, Vol. 107, No. 6. These open-access articles are distributed under Creative Commons licence CC-BY-NC 4.0.

National Xpert MTB/RIF Programme

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area

Assessing the programmatic management of drug-resistant TB

Ken Jost, BA, has the following disclosures to make:

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview

Multi Drug Resistant tuberculosis (MDR-TB)

CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service

7 Immunisation. 7.1 Immunisation coverage under 1 year. Trisha Ramraj and Witness Chirinda

Epidemic Levels of Drug Resistant Tuberculosis (MDR and XDR-TB) in a High HIV Prevalence Setting in Khayelitsha, South Africa

Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Multi-Ethnic Region, Xinjiang Uygur Autonomous Region, China

Name change of the invasive fruit fly and update on its pest status in South Africa

Annual surveillance report 2016

Drug-resistant tuberculosis (DR-TB) is a significant threat to efforts to end TB in

SOUTH AFRICA S TB BURDEN - OVERVIEW

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT

Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

The Emerging Threat of Multidrug-Resistant Tuberculosis: Global and Local Challenges and Solutions

Downloaded from:

Transmission of Extensively Drug-Resistant Tuberculosis in South Africa

Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Implications for the HIV Epidemic and Antiretroviral Therapy Rollout in South Africa

FIND and NDWG symposium Panel Discussion. Martina Casenghi, NDWG Core Group

Supplementary Appendix

Supplementary Appendix

Programmatically Selected Multidrug-Resistant Strains Drive the Emergence of Extensively Drug-Resistant Tuberculosis in South Africa

HA Convention 2016 : Special Topic Session 3 May 2016

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011

Responding to a TB Event Bismarck, North Dakota June 24-25, 2008

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

Treatment Outcomes for Patients with Extensively Drug-Resistant Tuberculosis, KwaZulu-Natal and Eastern Cape Provinces, South Africa

Annual surveillance report 2015

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye

M ultidrug resistant (MDR) tuberculosis (TB) has

Low treatment initiation among multi-drug resistant tuberculosis patients in Gauteng, South Africa, 2011

Health FITNESS & NUTRITION HEALTH CARE POLICY MENTAL HEALTH & BEHAVIOR. Mike Hutchings/Reuters ED PRINT REPRINTS SAVE SHARE

Background and Rationale for TB Infection Control

TB Program and Epidemic aka B2B

Index. Research Objective. Health Issues in SA Non-communicable diseases Diabetes Cancer Hypertension. Communicable Diseases HIV AIDS TB

Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing

Genotyping of Multidrug-Resistant Strains of Mycobacterium tuberculosis in the Limpopo Province. Kgasha Matete Olga

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012

Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending

Public Disclosure Authorized. Public Disclosure Authorized. Public Disclosure Authorized. Public Disclosure Authorized

March 24, 2007 will mark the 125th anniversary of Robert

Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan

11 Non-communicable diseases

TB Intensive San Antonio, Texas November 11 14, 2014

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Tuberculosis: The Big Picture And Challenge of Drug-resistance

CLINICAL EXPERIENCE OF TREATING XDR- TB AT JOSE PEARSON TB HOSPITAL

Laboratory Diagnosis for MDR TB

TOG The Way Forward

Roll-out of new TB drugs and short-course regimens in the Kyrgyz Republic

14 Burden of disease. Methodology. Pam Groenewald, Debbie Bradshaw, Candy Day and Ria Laubscher. Data source

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

TB 101 Disease, Clinical Assessment and Lab Testing

Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011

Optimising patient care in MDR TB with existing molecular screening tests in high burden countries

A tale of two settings: the role of the Beijing genotype in the epidemiology of MDR-TB.

Building a South African Exchange Program: Update and Future Goals

TB in the Southern African mining sector and across the sub-region STOP TB Partnership Board Meeting By Dr Aaron Motsoaledi Minister of Health South

Transcription:

Evolution of XDR-TB in KwaZulu-Natal A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal

Drug resistance among culture positive TB cases by South African Province (2001-2002) Any Drug Resistance (%) MDR (%) Province No History of Prior History of Prior TB No History of Prior History of Prior TB TB Treatment** Treatment** TB Treatment** Treatment** Eastern Cape 11.3 17.7 1.0 7.4 Free State*** 8.6 9.2 1.8 1.7 Gauteng 6.6 12.7 1.4 5.5 KwaZulu-Natal 6.6 18.4 1.7 7.7 Limpopo 7.1 17 2.4 6.8 Mpumalanga 9.4 23.4 2.6 13.7 North West 8.1 19.1 2.2 6.9 Western Cape 5.6 7.9 0.9 3.9 South Africa 7.7 15.5 1.6 6.6 (Weyer et al, 2004)

53 cases of XDR-TB diagnosed in CoSH in Tugela Ferry 1.1 1.0.9.8 (early 2005) Proportion Surviving.7.6.5.4.3.2.1 0.0 -.1 0 30 60 90 120 150 180 210 240 Days since Sputum Collected (Gandhi et al, 2006)

Questions What happened between 2002 and 2005? Where did these 53 XDR cases come from? Was (is) this a hospital outbreak at CoSH or a more wide spread problem? Are the 2001-2002 data an underrepresenting the MDR situation?

1396 cases suspected of PTB attending CoSH out-patient department 475 culture positive (2005)? infected in hospital 185 MDR 30 XDR 14 history of prior hospitalisation? infected in community 16 never hospitalised community transmission (Gandhi et al, 2006)

Questions What happened between 2002 and 2005? Where did these 53 XDR cases come from? Was (is) this a hospital outbreak at CoSH or a more wide spread problem? Are the 2001-2002 data an underrepresenting the MDR situation?

Proportion of F15/LAM4/KZN strains amongst genotyped isolates Year Total no. genotyped No. (%) KZN strains Total no. (%) MDR No. (%) MDR KZN strains 1994 322 6 (2) 9 (3) 4 (44) 1995 104 20 (19) 27 (26) 12 (44) 1996 140 21 (15) 56 (40) 15 (27) 1997 32 10 (31) 24 (75) 8 (33) 1998 23 2 (9) 8 (35) 1 (13) 1999 47 8 (17) 15 (32) 4 (27) 2000 45 14 (31) 28 (62) 8 (29) 2001 88 15 (17) 64 (73) 13 (20) 2002 165 13 (8) 38 (23) 10 (26) Total 966 109 (11) 269 (31) 75 (28) p < 0.0001 (Pillay and Sturm, 2007)

Fig 1. Resistance development in the KZN family of strains of Mycobacterium tuberculosis from 1994 till 2006 Resistance found for the first time in: Resistance to: 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 none IE IS ISE IR IRE IRET IREEtT IRS IRSE IRSEEtT IRSETCa IRSEEtTK IRSEEtFq IRSEEtKFq IRSEKFq I isoniazid; S streptomycin; E ethambutol; Et ethionamide; R rifampicin; T thiacetazone Ca capreomycin; K kanamycin/amikacin; Fq fluoroquinolones (Pillay and Sturm, CID, Dec. 2007)

Situation in KZN in 2006/07 Culture and DST results of all patients in KZN on sputum specimens received between 1 Jan. 2006 and 30 June 2007 Susceptibility testing done routinely for: isoniazide rifampicine ethambutol streptomycin kanamycine ofloxacin

KwaZulu-Natal Province Population size: 9,616,009 11 health districts divided in subdistricts

Differences in number of TB cases in districts of KZN District Population New TB cases MDR Cases XDR Cases Amajuba 477,472 150 47 2 ethekwini 3,152,405 11250 1526 90 ilembe 571,686 898 168 8 Sisonke 304,409 463 83 9 Ugu 718,221 788 265 15 Umgungundlovu 946,545 2833 418 53 Umkhanyakude 584,898 1016 45 4 Umzinyathi 465,660 1463 509 247 Uthukela 670,226 383 74 9 Uthungulu 903,822 1018 274 11 Zululand 820,661 466 211 4 Total 9,616,005 20728 3620 452

Differences in incidence of TB cases in districts of KZN Incidence of new TB Incidence of MDR Incidence of XDR District (per 100.000/yr) (per 100.000/yr) (per 100.000/yr) Amajuba 20.9 6.6 3.0 ethekwini 237.9 32.3 1.9 ilembe 104.7 19.6 0.9 Sisonke 101.4 18.2 2.0 Ugu 73.1 24.6 1.4 Umgungundlovu 199.5 29.4 3.7 Umkhanyakude 115.8 5.1 0.5 Umzinyathi 209.5 72.9 35.4 Uthukela 38.1 7.4 0.9 Uthungulu 75.1 20.2 0.8 Zululand 37.9 17.1 0.3 Total 143.7 25.1 3.1

Association between no. of new cases of TB diagnosed by culture and percentage MDR

Differences in rates of MDR and XDR cases in districts of KZN No. of MDR per No. of XDR per District 100 new TB cases 100 new TB cases Amajuba 31.3 1.3 ethekwini 13.6 0.8 ilembe 18.7 0.9 Sisonke 17.9 1.9 Ugu 33.6 1.9 Umgungundlovu 14.8 1.9 Umkhanyakude 4.4 0.4 Umzinyathi 34.8 16.9 Uthukela 19.3 2.3 Uthungulu 26.9 1.1 Zululand 45.3 0.9 Total 17.5 2.2

From 2005, CoSH is the only health care facility with culture diagnostics performed on all possible TB cases Includes Msinga (CoSH)

How resistant is our XDR TB?

Fig 1. Resistance development in the KZN family of strains of Mycobacterium tuberculosis from 1994 till 2006 Resistance found for the first time in: Resistance to: 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 none IE IS ISE IR IRE IRET IREEtT IRS IRSE IRSEEtT IRSETCa IRSEEtTK IRSEEtFq IRSEEtKFq IRSEKFq I isoniazid; S streptomycin; E ethambutol; Et ethionamide; R rifampicin; T thiacetazone Ca capreomycin; K kanamycin/amikacin; Fq fluoroquinolones (Pillay and Sturm, CID, Dec. 2007)

Genotypic resistance in F15/LAM4/KZN XDR isolates (n=52) Mutations in rss gene: 100 % resistance to streptomycin, kanamycine, amikacin and capreomycin Mutations in pcn A gene: 69 % resistance to pyrazinamide

MICs of M. tuberculosis isolates Table 2b: MICs of 11 M. tuberculosis isolates in Middlebrook 7H9 broth Median (range) MIC (mg/l) Susc. MDR XDR PAS 0.25 0.25 0.25 (0.12-0.25) Capreomycin 4 4 8 (4-16) Linezolid 2 (0.5-2) 0.5 (0.25-0.5) 1 (0.5-4) Merepenem 16 16 16 (8-32) Meropenem-clavulanic acid 1 1 (1-2) 1 (0.5-4)

How resistant is XDR M.tuberculosis in KZN? Most isolates are resistant to: 1. isoniazid 2. rifampicin 3. ethambutol 4. pyrazinamide 5. streptomycin 6. kanamycin 7. amikacin 8. capreomycin 9. ofloxacin 10.ethionamide

Tuberculosis in the Msinga sub-district compared with other parts of KwaZulu- Natal no. (%*) no. of MDR per no. of XDR per population new TB cases 100 new TB cases 100 new TB cases Msinga sub-district 160,000 1091 (0.68) 36.7 20 Umzinyathi without Msinga 305,660 372 (0.12) 29.3 7.8 districts with academic centre** (n=3) 4,683,848 15099 (0.32) 11 1 other districts ** (n=9) 4,466,497 4166 (0.09) 28 2 * percentage of the population ** MDR and XDR: average of the districts How does Msinga (CoSH) differ from the rest of the province?

Differences between Msinga subdistrict and the rest of the province Msinga sub-district Culture and DST on all on first contact No delay in DST results Rest of province Culture and DST on indication Delay in DST results No delay in appropriate treatment Delay in appropriate treatment

53 cases of XDR-TB diagnosed in CoSH in Tugela Ferry 1.1 1.0.9.8 Proportion Surviving.7.6.5.4.3.2.1 0.0 -.1 0 30 60 90 120 150 180 210 240 Days since Sputum Collected (Gandhi et al, 2006)

Referral for treatment of MDR/XDR cases Total number of MDR/XDR diagnosed between 1 Jan 2006 and 30 June 2007 3620 Total number referred for treatment to MDR/XDR referral hospital 1439 (40%) Waiting list for admission

Is Msinga (CoSH) different from the rest of the province? May be not! Many patients in the rest of the province die: before a specimen is taken or before the DST results become available

Clonal spread? If so, did it start in Msinga /Tugela Ferry/CoSH?

Whole genome sequencing F15/LAM4/KZN XDR isolates 8 sequences completed all same mutations in resistance genes

Geographical distribution of sequenced XDR isolates 8 isolates 7 locations 4 districts Tugela Ferry

Whole genome sequencing F15/LAM4/KZN XDR isolates 8 sequences completed All same mutations in resistance genes Isolates from 7 different geographical locations 4 districts Suggests clonal spread number needs to be extended

Clonal spread? If so, did it start in Msinga /Tugela Ferry/CoSH?

Tuberculosis in the Msinga sub-district compared with other parts of KwaZulu- Natal no. (%*) no. of MDR per no. of XDR per population new TB cases 100 new TB cases 100 new TB cases Msinga sub-district 160,000 1091 (0.68) 36.7 20 Umzinyathi without Msinga 305,660 372 (0.12) 29.3 7.8 districts with academic centre** (n=3) 4,683,848 15099 (0.32) 11 1 other districts ** (n=9) 4,466,497 4166 (0.09) 28 2 * percentage of the population ** MDR and XDR: average of the districts

Origin of XDR isolates in 1 st half of 2005 (laboratory database) Tugela Ferry Other locations January - March 15 6 April - June 17 11 Did it start in Tugela Ferry? We will never know!

Conclusions KwaZulu-Natal has an enormous TB burden MDR and XDR strains are present throughout the province F15/LAM4/KZN isolates from 2005 were already TDR Sequence data suggest clonal spread of the XDR phenotype of F15/LAM4/KZN Prevalence data and time-of-first appearance data suggest that it may have started in Msinga district/tugela Ferry/CoSH

The team Durban Prashini Moodley Manormoney Pillay Staff and students of the TB research laboratory in at NRMSM Tugela Ferry Tony Moll Staff at Church of Scotland Hospital Albert Einstein/Yale Sarita Shah Neel Gandhi Gerald Friedland Bill Jacobs and his team